417. Combination Brain and Systemic Injections of AAV Results in Whole Body Therapy and Extension of Lifespan in the Niemann-Pick Mouse

• Published in: Molecular therapy Vol. 13; no. S1; p. S160
• Main Authors: Passini, Marco A, Bu, Jie, Fidler, Jonathan A, Foley, Joseph W, Dodge, James C, Ziegler, Robin J, Yang, Wendy W, Clarke, Jennifer, Taksir, Tatyana V, Griffiths, Denise A, Zhao, Michael A, O'riordan, Catherine R, Shihabuddin, Lamya S, Schuchman, Edward H, Cheng, Seng H
• Format: Journal Article
• Language: English
• Published: Milwaukee Elsevier Limited 01-05-2006
• Subjects: Amphetamines; Carotid arteries; Disease; Gene therapy; Growth factors; Lasers; Monkeys & apes; Ophthalmology; Parkinson's disease; Primates; Toxicity; Vectors (Biology); Australia; Perth Western Australia Australia
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1016/j.ymthe.2006.08.481

The majority of lysosomal storage diseases contain both CNS and visceral pathology. Many experimental designs use either intracranial injection of viral vectors to treat the neurodegenerative phenotype of the disease, or systemic delivery to treat the viscera. In this study, we tested whether a combination of brain and systemic injections of adeno-associated virus (AAV) vectors could increase lifespan, provide whole body reversal of pathology, and improve motor and cognitive function in the acid sphingomyelinase knock out (ASMKO) mouse model of Niemann-Pick disease. ASMKO mice at 4 weeks of age were injected systemically with AAV8- hASM, and subsequently, the same animals were injected into the brain with AAV2-hASM. All the mice treated by combination injections survived to 54 weeks of age. This was a significant improvement over untreated ASMKO mice, animals that had been treated by systemic injection only or by brain injection only, which had median life spans of 34 weeks, 45 weeks, and 43 weeks, respectively. Thus the brain alone injections did not protect animals from dying. Animals treated by the combination therapy also displayed normal weight gain, and significant functional recovery on the rotarod (motor task) and the Barnes maze (cognitive task) throughout the time course of the study. These data support the contention that combination therapy can improve the quality of life before and within the time frame of extended survival.